*https://doi.org/10.33472/AFJBS.6.Si3.2024.3492-3510*

African Journal of Biological Sciences

Journal homepage: http://www.afjbs.com

Research Paper Open Access

# Microneedle Therapy for Neurological Disorders: Progress and Challenges

**Prashant Kumar[1], Sakshi[2], Priti Tiwari[3], Kunal[4], Shikha Parmar[5], Km. Saiphali[6], Puneet Nirmal[7*]**

[1]Professor, Kanpur Institute of Technology and Pharmacy
[2]Assistant Professor, Noida Institute of Engineering and Technology (Pharmacy Institute), Plot no 19, Knowledge Park II, Greater Noida, Uttar Pradesh, India-201206
[2]PhD Scholar, NIMS Institute of Pharmacy, NIMS University Rajasthan, Jaipur 303121 India
[3]Assistant Professor (Pharmaceutical Chemistry), School of Pharmacy, Noida International University, Plot No. 1, Yamuna Expressway, Sector 17A, Uttar Pradesh- 203201
[3]PhD Scholar, IFTM UNIVERSITY, Moradabad, U.P: 244102
[4]R.P. Educational Trust Group of Institutions Bastara, Karnal
[5]GNIT College of Pharmacy, Greater Noida, Director & Professor
[6]Asst. Professor (Ph. Quality assurance) Panipat institute of engineering and technology(Department of pharmacy), Panipat Haryana
[7*]Assistant Professor, Lloyd Institute of Management and Technology, Plot No:11, Knowledge Park-II, Greater Noida, Uttar Pradesh, India- 201306
[7*]PhD Scholar, NIMS Institute of Pharmacy, NIMS University Rajasthan, Jaipur 303121 India

**Corresponding author Email:** puneetnirmal1335@gmail.com
Orcid id: 0000-0002-3260-7371

**Article Info**

Volume 6, Issue Si3, August 2024

Received: 23 June 2024

Accepted: 13 July 2024

Published: 05 August 2024

*doi: 10.33472/AFJBS.6.Si3.2024.3492-3510*

**ABSTRACT:**

Microneedle (MN) therapy is emerging as a promising approach for the treatment of neurological disorders, leveraging its minimally invasive nature to enhance drug delivery and monitoring capabilities. This review article comprehensively explores the advancements in microneedle technology, focusing on its applications in neurological diseases. It discusses various fabrication methods, including photolithography and 3D printing, and highlights the mechanisms of drug transfer through microneedles, such as poke and flow and poke and release. While microneedles offer significant advantages, including improved drug permeability and the ability to monitor physiological parameters, they also face challenges such as scaling difficulties, variability in drug delivery, potential for inflammation, and limitations in dosing range. The review underscores the potential of microneedles as theranostic devices, facilitating both diagnostics and therapeutic applications by enabling direct access to interstitial fluids for biomarker detection. Furthermore, the article examines the current clinical status and commercial availability of microneedle devices, aiming to provide insights for researchers and clinicians interested in this innovative delivery system. Overall, the review highlights the progress made in microneedle therapy for neurological disorders while addressing the ongoing challenges that need to be overcome for broader clinical implementation.

**Keywords**: Microneedle therapy, neurological disorders, drug delivery, blood-brain barrier, Alzheimer's disease, Parkinson's disease

## 1. INTRODUCTION

Neurological disorders encompass a wide array of conditions that affect the brain, spinal cord, and peripheral nerves[1]. These disorders can result from genetic mutations, environmental factors, infections, and injuries, leading to functional impairments in various body systems. Among the most well-known neurological disorders are Alzheimer's disease, Parkinson's disease, Multiple Sclerosis (MS), and Epilepsy. Alzheimer's Disease is a progressive neurodegenerative disorder characterized by memory loss, cognitive decline, and behavioral changes. It primarily affects the elderly and is the most common cause of dementia, accounting for approximately 60-70% of cases[2]. The pathology of Alzheimer's involves the accumulation of amyloid plaques and neurofibrillary tangles in the brain, leading to neuronal death and brain atrophy. Parkinson's Disease is a neurodegenerative disorder that primarily impacts motor function[3]. It is marked by tremors, rigidity, bradykinesia (slowness of movement), and postural instability. The disease results from the degeneration of dopamine-producing neurons in the substantia nigra, a region of the brain critical for movement control. Non-motor symptoms, such as depression and cognitive impairment, are also common. Multiple Sclerosis is an autoimmune disorder where the body's immune system attacks the myelin sheath, the protective covering of nerve fibers in the central nervous system[4]. This leads to communication problems between the brain and the rest of the body, causing symptoms such as fatigue, difficulty walking, numbness, and muscle weakness. MS can be relapsing-remitting or progressive, with varying degrees of disability[5]. Epilepsy is a neurological condition characterized by recurrent, unprovoked seizures due to abnormal electrical activity in the brain. Seizures can vary widely in their manifestation, from brief lapses in attention to severe convulsions[6]. Epilepsy can result from genetic predispositions, brain injuries, infections, or developmental disorders. Neurological disorders significantly impact society. They are leading causes of disability and mortality, contributing to substantial healthcare costs and economic burdens. For instance, the World Health Organization (WHO) estimates that over 50 million people worldwide live with epilepsy, and around 50 million people have dementia, including Alzheimer's disease[7]. The aging population and increased life expectancy further amplify the prevalence and impact of these disorders, underscoring the need for effective therapeutic interventions. The current state of treatment for neurological disorders varies widely, but in many cases, it remains inadequate[8]. For instance, while there are medications available to manage the symptoms of Parkinson's disease, such as Levodopa, they do not cure the disease or halt its progression. Similarly, disease-modifying therapies for Multiple Sclerosis, like interferon-beta, aim to reduce the frequency of relapses but do not provide a cure. The necessity for new therapies and improvements in existing treatments is paramount for several reasons. Firstly, many current therapies primarily address symptoms rather than the underlying causes of neurological disorders[9]. For example, cholinesterase inhibitors used in Alzheimer's disease can temporarily improve symptoms but do not stop or slow down the progression of the disease. Thus, there is a critical need for disease-modifying treatments that can alter the course of these disorders. Secondly, the side effects and limitations of current treatments necessitate the development of safer and more effective options[10]. For instance, the long-term use of Levodopa in Parkinson's disease often leads to motor complications such as dyskinesia (involuntary movements), which can significantly affect the quality of life. Similarly, antiepileptic drugs can cause cognitive and behavioral side effects, necessitating better-tolerated alternatives[11]. Furthermore, the complexity and heterogeneity of neurological disorders require personalized approaches to treatment. Advances in genomics, biomarkers, and neuroimaging hold the promise of tailoring therapies to individual patients, enhancing efficacy and reducing adverse effects. Personalized medicine can potentially

revolutionize the management of neurological disorders by targeting specific molecular and genetic profiles[12].



Figure 1: Schematics diagram of Microneedle

**Historical Perspective**

**Early Treatments and Approaches**

The treatment of neurological disorders has evolved significantly over centuries, beginning with rudimentary methods that often did more harm than good. Early approaches to managing neurological disorders were primarily based on limited medical knowledge and were heavily influenced by superstitions and misconceptions about the brain and nervous system[4].

**Traditional Methods:** In ancient times, trepanation, the practice of drilling holes into the skull, was one of the earliest known surgical interventions for treating headaches, epilepsy, and mental disorders. It was believed to release evil spirits or pressure from the brain[6,9]. Although crude and dangerous, trepanation is one of the earliest documented attempts at neurosurgery. In the realm of early pharmacology, herbal remedies and concoctions were commonly used to treat symptoms of neurological disorders[3]. For instance, the use of opium for pain relief dates back to ancient civilizations. Ancient Egyptians used various plant extracts, such as mandrake and henbane, believed to possess sedative and antiepileptic properties. However, these treatments were largely empirical and lacked scientific validation[13].

**Milestones in Neurological Disorder Treatment**: The development of more structured medical knowledge during the Renaissance and Enlightenment periods marked significant milestones in the treatment of neurological disorders[14]. One notable figure is Thomas Willis, an English physician in the 17th century, often referred to as the "father of neurology." Willis

made pioneering contributions to the understanding of brain anatomy and function, which laid the foundation for modern neurology[3]. The 19th century saw the emergence of more sophisticated surgical techniques and diagnostic tools. The invention of the ophthalmoscope by Hermann von Helmholtz in 1851 allowed for the examination of the retina, providing insights into intracranial pressure and neurological conditions[11]. This period also witnessed the advent of neuroanatomical studies by scientists like Santiago Ramón y Cajal, whose work on the structure of the nervous system earned him the Nobel Prize[15].

**Evolution of Therapies**

The 20th century brought about transformative changes in the treatment of neurological disorders, driven by scientific advancements and a deeper understanding of the nervous system.

**Major Breakthroughs**: One of the most significant breakthroughs was the discovery of the blood-brain barrier (BBB) in the early 20th century, which revolutionized the understanding of drug delivery to the brain. This discovery spurred the development of pharmacological treatments specifically designed to cross the BBB and target neurological disorders. The mid-20th century saw the development of key drugs that became cornerstones in the treatment of neurological disorders[16]. In 1960, Levodopa was introduced as a revolutionary treatment for Parkinson's disease, significantly improving motor symptoms by replenishing dopamine levels in the brain. Similarly, the discovery of anticonvulsant drugs like phenytoin and valproate provided effective management of epilepsy, reducing the frequency and severity of seizures[17].

**Development of New Surgical Techniques**: Advances in neurosurgery also marked a significant evolution in the treatment of neurological disorders. The introduction of stereotactic surgery in the 1940s allowed for precise targeting of brain regions, leading to more effective and less invasive interventions[18]. Deep Brain Stimulation (DBS), first developed in the 1980s, emerged as a groundbreaking treatment for Parkinson's disease and other movement disorders. DBS involves the implantation of electrodes in specific brain areas to modulate neural activity, providing symptom relief for patients unresponsive to medication[19].

**Shifts in Treatment Paradigms**: The latter half of the 20th century and early 21st century witnessed a paradigm shift in the approach to treating neurological disorders. The focus expanded from merely managing symptoms to understanding and targeting the underlying disease mechanisms[4]. This shift was driven by advances in molecular biology, genetics, and neuroimaging. The Human Genome Project, completed in 2003, played a pivotal role in identifying genetic factors associated with neurological disorders[1,5]. This knowledge paved the way for the development of targeted therapies, such as gene therapy, which aims to correct genetic mutations responsible for conditions like spinal muscular atrophy and certain forms of epilepsy. In recent years, the integration of technology in neurological treatment has opened new frontiers[12]. Neuroprosthetics, brain-computer interfaces, and the use of artificial intelligence in diagnostics and treatment planning represent the cutting-edge evolution of neurological therapies. These innovations hold the promise of not only improving treatment outcomes but also enhancing the quality of life for individuals with neurological disorders[20].




Fig 2. Schematic Diagram of Microneedle (MN)-Based Drug Delivery Approaches and Cross-Section of the Skin's Upper Layer. The Approaches Include: (a) Solid MNs, (b) Coated MNs, (c) Hollow MNs, (d) Dissolving MNs, and (e) Hydrogel-Forming MNs. The Step-by-Step Process for Each Approach is Numbered from 1 to 3. Representative Microscopic Images of MN Types and Examples of Deliverable Payloads, Including Drugs and Bio-Macromolecules, are Also Shown[21].

## Current Therapies

### Pharmacological Treatments

Pharmacological treatments remain a cornerstone in the management of neurological disorders. Medications are developed to address various aspects of these conditions, including symptom relief, disease modification, and neuroprotection[6]. For instance, in the treatment of Parkinson's disease, Levodopa is widely used to replenish dopamine levels, while dopamine agonists and MAO-B inhibitors serve as adjunct therapies[22]. Alzheimer's disease treatment often involves cholinesterase inhibitors, like Donepezil, and NMDA receptor antagonists, such as Memantine, to manage cognitive symptoms. Antiepileptic drugs (AEDs) like phenytoin, valproate, and newer agents such as levetiracetam are crucial in controlling seizures[11]. Multiple Sclerosis (MS) management includes disease-modifying therapies (DMTs) like interferon-beta, glatiramer acetate, and newer oral medications like fingolimod and dimethyl fumarate[23]. The effectiveness of pharmacological treatments largely depends on their mechanisms of action, which are designed to target specific pathways involved in neurological

disorders. Levodopa, for example, is converted to dopamine in the brain, compensating for the deficiency seen in Parkinson's disease[19]. Cholinesterase inhibitors increase acetylcholine levels by inhibiting its breakdown, which can temporarily alleviate symptoms of Alzheimer's disease. AEDs work through various mechanisms, such as enhancing GABAergic inhibition (e.g., benzodiazepines), blocking sodium channels (e.g., phenytoin), or inhibiting T-type calcium channels (e.g., ethosuximide)[3,9]. In MS, interferon-beta modulates the immune response to reduce inflammation and neurodegeneration. While many pharmacological treatments have significantly improved the quality of life for patients with neurological disorders, they also have notable limitations[24]. For instance, Levodopa is highly effective in early Parkinson's disease but often leads to motor complications, such as dyskinesia, after long-term use[8]. Cholinesterase inhibitors in Alzheimer's disease provide only modest benefits and do not halt disease progression. AEDs can be effective in controlling seizures, but about one-third of epilepsy patients are refractory to available medications[12]. Moreover, DMTs for MS can reduce relapse rates and slow disease progression but do not offer a cure and may have significant side effects, including increased infection risk and liver toxicity[25].

**Non-Pharmacological Treatments**

**Physical Therapy and Occupational Therapy**: Non-pharmacological treatments play a vital role in managing neurological disorders, particularly in enhancing functional abilities and improving the quality of life[18]. Physical therapy (PT) focuses on improving mobility, strength, and coordination through exercises, gait training, and balance activities. It is crucial for patients with Parkinson's disease, stroke, and MS[5]. Occupational therapy (OT) helps patients develop and maintain daily living skills, such as dressing, bathing, and eating, and may involve adaptive techniques and assistive devices to promote independence[26].

**Cognitive Behavioral Therapy (CBT)**: CBT is an evidence-based psychological intervention that helps patients manage symptoms of neurological disorders, particularly those related to mental health. It is effective in treating depression and anxiety in patients with Parkinson's disease and MS[5.9]. CBT involves identifying and challenging negative thought patterns and developing coping strategies to improve emotional well-being. For epilepsy patients, CBT can help manage stress and anxiety, which can trigger seizures[27].

**Surgical Interventions**

**Types of Surgeries**: Surgical interventions are considered when pharmacological and non-pharmacological treatments are insufficient. Deep Brain Stimulation (DBS) is a prominent surgical technique used for Parkinson's disease, essential tremor, and dystonia[28]. It involves implanting electrodes in specific brain regions, such as the subthalamic nucleus, and connecting them to a pulse generator that modulates abnormal neural activity. Another surgical approach is vagus nerve stimulation (VNS) for epilepsy, where a device is implanted to stimulate the vagus nerve, reducing seizure frequency. Intractable epilepsy may also be treated with resective surgery, where the seizure focus in the brain is surgically removed[29].

**Success Rates and Risks**: DBS has shown substantial success in reducing motor symptoms and improving the quality of life in Parkinson's disease patients, with studies indicating significant long-term benefits[30]. However, it carries risks such as infection, bleeding, and hardware complications[4]. VNS has been effective in reducing seizures in epilepsy patients who do not respond to medications, but potential side effects include hoarseness, throat pain, and heart rate changes[12]. Resective epilepsy surgery can lead to seizure freedom in a significant proportion of patients, but it involves risks like cognitive changes and neurological deficits, depending on the brain region operated on[31].

**Emerging Therapies**

**Stem Cell Therapy**: Stem cell therapy is an emerging field with the potential to revolutionize the treatment of neurological disorders[18]. It involves the transplantation of stem cells or their derivatives to replace damaged neurons or modulate the disease environment. For example, in Parkinson's disease, stem cells could potentially be used to generate dopamine-producing neurons, restoring normal brain function[2,11]. Early clinical trials have shown promise, but challenges remain in ensuring the safety, efficacy, and long-term integration of transplanted cells[32].

**Gene Therapy**: Gene therapy aims to correct genetic defects or modulate gene expression to treat neurological disorders[33]. Techniques like CRISPR-Cas9 and viral vector-mediated gene delivery are being explored for conditions such as spinal muscular atrophy (SMA), where gene replacement therapy has shown remarkable success[10]. In SMA, the delivery of a functional copy of the SMN1 gene has significantly improved motor function and survival. However, gene therapy faces challenges like immune responses, delivery efficiency, and long-term effects[34].

**Immunotherapy**: Immunotherapy leverages the immune system to target and treat neurological disorders. In MS, immunomodulatory therapies aim to reduce the autoimmune attack on myelin[3]. Monoclonal antibodies, such as ocrelizumab, target B cells and have shown efficacy in reducing relapse rates and slowing disease progression[11,9]. For Alzheimer's disease, immunotherapy approaches targeting amyloid-beta plaques, such as aducanumab, have generated significant interest, although their clinical benefits are still under investigation. Immunotherapy must balance efficacy with the risk[35].

**Mechanisms of Action**

**Understanding Pathophysiology**

**Biological Underpinnings of Key Neurological Disorders**: The pathophysiology of neurological disorders involves complex biological processes that result in the dysfunction of the nervous system. Understanding these processes is crucial for developing effective therapies, as described schematically in Figure 2.

**Alzheimer's Disease**: The primary pathological hallmarks of Alzheimer's disease are the accumulation of amyloid-beta plaques and neurofibrillary tangles composed of hyperphosphorylated tau protein[12,8]. These abnormalities lead to neuronal death, synaptic dysfunction, and brain atrophy. Amyloid-beta plaques are thought to disrupt cell communication and activate immune responses that trigger inflammation and oxidative stress[4]. Tau tangles, on the other hand, destabilize the microtubule network within neurons, impairing cellular transport mechanisms and leading to cell death[36].

**Parkinson's Disease**: Parkinson's disease is characterized by the progressive loss of dopaminergic neurons in the substantia nigra, a region of the brain involved in movement control. The death of these neurons leads to a deficiency of dopamine, a neurotransmitter essential for coordinating movement[20,8]. The presence of Lewy bodies, abnormal aggregates of alpha-synuclein protein, is another pathological feature. These aggregates disrupt cellular functions and contribute to neuronal death[37].

**Multiple Sclerosis (MS)**: MS is an autoimmune disorder where the immune system mistakenly attacks the myelin sheath, the protective covering of nerve fibers in the central nervous system[8,19]. This demyelination disrupts the efficient transmission of electrical impulses along the nerves, leading to symptoms such as muscle weakness, coordination problems, and sensory disturbances. Inflammation and the formation of sclerotic plaques (lesions) in the brain and spinal cord are central to MS pathophysiology[38].

**Epilepsy**: Epilepsy is characterized by recurrent, unprovoked seizures caused by abnormal electrical activity in the brain. The pathophysiology of epilepsy can vary widely but often

involves an imbalance between excitatory and inhibitory neurotransmission[18]. Excessive excitation or insufficient inhibition can lead to hyperexcitability of neurons, resulting in seizure activity. Structural abnormalities, genetic mutations, and brain injuries can all contribute to the development of epilepsy[39].




Fig 3. mechanism of microneedle

**Therapeutic Targets**

**Neurotransmitters, Neural Circuits, and Molecular Targets**: Therapeutic targets in neurological disorders focus on modulating neurotransmitter systems, neural circuits, and specific molecular pathways to restore normal function or slow disease progression[13].

**Neurotransmitters**: In Parkinson's disease, the primary therapeutic target is the dopaminergic system. Levodopa, the precursor of dopamine, is used to replenish dopamine levels, while dopamine agonists stimulate dopamine receptors[22,9]. In Alzheimer's disease, therapies targeting cholinergic deficits involve cholinesterase inhibitors, which increase acetylcholine levels by inhibiting its breakdown. GABAergic and glutamatergic systems are targeted in epilepsy treatments to balance excitatory and inhibitory neurotransmission[40].

**Neural Circuits**: Deep Brain Stimulation (DBS) targets specific neural circuits to modulate abnormal activity[18]. In Parkinson's disease, DBS of the subthalamic nucleus or globus pallidus can alleviate motor symptoms by normalizing disrupted neural pathways. Similarly, in epilepsy, responsive neurostimulation devices target seizure foci to prevent seizure propagation by delivering electrical stimulation to abnormal circuits[41].

**Molecular Targets**: Advances in molecular biology have identified numerous molecular targets for therapeutic intervention. In MS, monoclonal antibodies such as natalizumab target cell adhesion molecules to prevent immune cells from crossing the blood-brain barrier and attacking myelin[33]. In Alzheimer's disease, amyloid-beta-targeting therapies aim to reduce plaque formation and promote clearance of existing plaques[15]. Gene therapy approaches target specific genetic mutations, such as those in the SMN1 gene in spinal muscular atrophy, to restore normal protein function[42].

**Biomarkers and Diagnostics**

**Advances in Diagnostic Tools**: The development of advanced diagnostic tools has revolutionized the early detection and monitoring of neurological disorders. Neuroimaging techniques such as magnetic resonance imaging (MRI), positron emission tomography (PET), and functional MRI (fMRI) provide detailed images of brain structure and function[4,10]. These tools allow for the identification of structural abnormalities, metabolic changes, and functional disruptions associated with various neurological disorders[43].

**Role of Biomarkers in Personalized Medicine**: Biomarkers are measurable indicators of biological processes or disease states and play a crucial role in personalized medicine. In Alzheimer's disease, cerebrospinal fluid (CSF) levels of amyloid-beta and tau proteins serve as biomarkers for early diagnosis and disease progression[18,9]. Genetic testing for mutations in genes such as APP, PSEN1, and PSEN2 can identify individuals at risk for familial Alzheimer's

disease. In Parkinson's disease, alpha-synuclein levels in CSF and blood are being explored as potential biomarkers[2,8]. Biomarkers also guide treatment decisions and monitor therapeutic responses. In MS, biomarkers such as neurofilament light chain (NfL) in blood and CSF reflect neuronal damage and can predict disease activity and treatment response[19]. In epilepsy, continuous monitoring of seizure frequency and intensity through wearable devices provides real-time data for optimizing treatment plans[44].

**Recent Scientific Advances**

**Notable Studies and Their Findings**: In recent years, numerous studies have significantly advanced our understanding of neurological disorders and their treatment.

**Alzheimer's Disease**: A landmark study in the field of Alzheimer's research was the discovery of the role of amyloid-beta and tau proteins in disease progression[22]. Recent trials, such as those for aducanumab, have shown that targeting amyloid plaques can potentially slow cognitive decline, marking a significant breakthrough despite ongoing debates about its clinical efficacy[4,19]. Another notable study identified the TREM2 gene, which is involved in microglial function and amyloid plaque clearance, offering new avenues for therapeutic intervention[45].

**Parkinson's Disease**: Advances in genetics have uncovered mutations in genes like LRRK2 and GBA, which are associated with Parkinson's disease[5]. These findings have led to the development of targeted therapies, such as LRRK2 inhibitors, currently in clinical trials. Additionally, studies on the gut-brain axis have provided insights into the role of the microbiome in Parkinson's disease, suggesting that gut health could influence disease progression and offering potential new targets for treatment[46].

**Multiple Sclerosis (MS)**: Recent research has highlighted the role of B cells in MS, leading to the development of B cell-depleting therapies like ocrelizumab. Studies have also shown that early and aggressive treatment with disease-modifying therapies can significantly improve long-term outcomes for MS patients[18]. Advances in imaging techniques, such as high-resolution MRI, have enhanced the ability to detect and monitor MS lesions, aiding in early diagnosis and treatment optimization[47].

**Epilepsy**: Advances in neuroimaging and genetics have improved the understanding of epilepsy's heterogeneity. The identification of mutations in genes like SCN1A has led to more precise diagnostic tools and personalized treatment approaches[33]. Recent studies have also focused on the potential of neuromodulation techniques, such as transcranial magnetic stimulation (TMS) and responsive neurostimulation (RNS), to reduce seizure frequency in refractory epilepsy[48].

**Innovative Research Approaches**

**Use of Technology**: The integration of advanced technologies has revolutionized research in neurological disorders.

**Artificial Intelligence (AI) in Diagnostics**: AI and machine learning algorithms are being used to analyze complex datasets from neuroimaging, genomics, and clinical records, enhancing the accuracy and speed of diagnosis[36]. For instance, AI algorithms can detect early signs of Alzheimer's disease in brain scans years before clinical symptoms appear. Similarly, machine learning models can predict the progression of Parkinson's disease based on motor and non-motor symptoms[49].

**Wearable Devices for Monitoring**: Wearable devices, such as smartwatches and biosensors, provide continuous monitoring of physiological parameters[21]. In epilepsy, wearable EEG devices can detect seizures in real time, alerting caregivers and enabling timely intervention. For Parkinson's disease, wearable sensors can monitor gait and tremors, allowing for

personalized adjustments to treatment plans[19]. These devices not only improve patient management but also generate large amounts of data for research[50].

**Collaboration Between Academia, Industry, and Clinical Practice**: Effective collaboration between academic researchers, pharmaceutical companies, and clinical practitioners is essential for translating scientific discoveries into clinical applications[3].

**Translational Research**: Academia-industry partnerships facilitate the translation of basic research findings into new therapies. For example, the collaboration between universities and biotech companies has accelerated the development of gene therapies for neurological disorders[22]. Clinical trials conducted in collaboration with academic centers ensure rigorous testing and validation of new treatments[51].

**Multidisciplinary Teams**: The complexity of neurological disorders requires a multidisciplinary approach. Teams comprising neurologists, geneticists, bioinformaticians, and engineers work together to address the multifaceted challenges of these diseases[40]. For instance, the development of brain-computer interfaces (BCIs) for patients with severe motor impairments involves expertise in neuroscience, computer science, and robotics[52].

**Patient-Centered Research**: Engaging patients and advocacy groups in the research process ensures that the research addresses real-world needs and priorities[18]. Patient-centered research initiatives, such as the Parkinson's Progression Markers Initiative (PPMI), involve patients in study design, data collection, and dissemination of results. This approach enhances the relevance and impact of research findings[53]. Recent scientific advances and innovative research approaches have significantly enhanced our understanding and treatment of neurological disorders[3,9]. The integration of technology, interdisciplinary collaboration, and patient-centered research are driving progress towards more effective and personalized therapies. Continued investment in research and innovation is essential to address the unmet needs of patients with neurological disorders and to improve their quality of life[54].

**Challenges in Therapy Development**

**Complexity of Neurological Diseases**: Neurological diseases are inherently complex due to the intricate structure and function of the nervous system[12]. Each disorder can present with a wide range of symptoms and disease trajectories, influenced by genetic, environmental, and lifestyle factors[55]. For example, Alzheimer's disease involves not just amyloid-beta plaques and tau tangles but also neuroinflammation, vascular changes, and metabolic dysfunctions. Parkinson's disease, while primarily characterized by dopaminergic neuron loss, also involves non-motor symptoms such as autonomic dysfunction and neuropsychiatric manifestations[21,27]. The heterogeneity within and between these disorders makes it challenging to identify universal therapeutic targets and develop one-size-fits-all treatments[56].

**Limitations in Current Research Methodologies**: Traditional research methodologies often fall short in capturing the full complexity of neurological disorders[12]. Animal models, commonly used to study disease mechanisms and test potential therapies, frequently fail to replicate the human disease accurately[57]. This is particularly evident in Alzheimer's disease, where many therapies that showed promise in mouse models failed in human trials. Additionally, the blood-brain barrier poses a significant challenge, limiting the delivery of therapeutic agents to the brain[21,8]. The lack of robust biomarkers for early diagnosis and disease progression further complicates the development and evaluation of new therapies. Advanced techniques like induced pluripotent stem cells (iPSCs), organoids, and high-resolution imaging are beginning to address some of these limitations, but they are still in relatively early stages of development and application[58].

**Clinical and Regulatory Hurdles**

**Design and Execution of Clinical Trials**: Clinical trials for neurological disorders face several unique challenges. First, recruiting and retaining participants can be difficult due to the progressive and debilitating nature of many neurological diseases[11]. Trials often require long durations to observe significant changes in disease progression, making them costly and time-consuming. Additionally, the subjective nature of many neurological symptoms complicates the measurement of treatment efficacy[29]. Standardizing outcome measures and developing reliable biomarkers are critical but challenging tasks[5]. For example, in Alzheimer's disease, cognitive decline is typically measured using scales like the ADAS-Cog, which may not capture subtle changes or reflect real-world improvements[59].

**Regulatory Approval Processes**: The regulatory approval process for new therapies is rigorous and can be particularly challenging for neurological drugs. Regulatory agencies require extensive evidence of safety and efficacy, often through multiple phases of clinical trials[33]. The high failure rate of drugs in late-stage trials adds to the cost and time required to bring new treatments to market[40]. Additionally, the approval process must adapt to the evolving landscape of personalized medicine, where treatments are tailored to individual genetic profiles or disease subtypes. This requires regulators to balance the need for thorough evaluation with the urgency of providing patients access to potentially life-saving treatments[60].

**Economic and Social Barriers**

**Funding and Resource Allocation**: Developing new therapies for neurological disorders is an expensive endeavor, requiring substantial financial investment from both public and private sectors[19,21]. Funding for research is often limited and highly competitive, with many promising projects struggling to secure the necessary resources[20]. Pharmaceutical companies may be hesitant to invest in neurological drug development due to the high risk of failure and the lengthy and costly approval process[61]. Moreover, funding is not evenly distributed across all neurological disorders, with more common conditions like Alzheimer's and Parkinson's receiving a disproportionate share of resources compared to rarer disorders[62].

**Accessibility and Affordability of Treatments**: Even when new therapies are developed and approved, ensuring they are accessible and affordable to all patients is a significant challenge. High costs of new drugs can limit their availability, particularly in low- and middle-income countries[28]. For example, innovative treatments like gene therapies and monoclonal antibodies can cost hundreds of thousands of dollars per patient, creating substantial economic barriers. Health insurance coverage and reimbursement policies vary widely, impacting patients' ability to access necessary treatments[2]. Additionally, geographical disparities in healthcare infrastructure and specialist availability further limit access to advanced neurological care[63].

**Future Directions**

**dPotential Game-Changing Therapies on the Horizon**: The future of neurological disorder therapy holds immense promise, driven by cutting-edge research and technological advancements. Several potential game-changing therapies are currently under investigation and show significant potential to transform patient care[64].

**Gene Editing and Therapy**: Gene editing technologies, particularly CRISPR-Cas9, offer the potential to correct genetic mutations underlying many neurological disorders. For example, research is underway to use gene editing to address mutations in the HTT gene responsible for Huntington's disease, potentially halting or reversing the disease's progression[23,9]. Gene therapy, which involves delivering functional copies of genes to replace defective ones, is also advancing[33]. One notable success is the approval of onasemnogene abeparvovec

(Zolgensma) for spinal muscular atrophy (SMA), which has shown remarkable efficacy in improving motor function and survival in infants with SMA[65].

**Neuroprotective Agents**: Developing drugs that can protect neurons from degeneration is a major focus in neurological research. Compounds that target oxidative stress, mitochondrial dysfunction, and neuroinflammation are being explored for diseases like Alzheimer's and Parkinson's[22]. One promising area is the development of small molecules that enhance the activity of neurotrophic factors, which support neuron survival and function[38]. Clinical trials are ongoing for drugs like Nilotinib, originally used for leukemia, which may have neuroprotective effects in Parkinson's disease[66].

**Regenerative Medicine**: Stem cell therapy aims to replace damaged neurons and support neural regeneration. Research is progressing on using induced pluripotent stem cells (iPSCs) to generate patient-specific neurons for transplantation[55]. In Parkinson's disease, clinical trials are testing the transplantation of dopaminergic neurons derived from iPSCs to restore dopamine production in the brain[4]. Similarly, research in MS focuses on promoting remyelination through the use of stem cells to repair damaged myelin sheaths[67].

**Innovations in Drug Delivery**

**Nanotechnology and Targeted Delivery Systems**: Effective drug delivery to the brain is a significant challenge due to the blood-brain barrier (BBB), which restricts most therapeutic agents from entering the central nervous system[8]. Innovations in nanotechnology and targeted delivery systems are addressing this challenge by enhancing the precision and efficacy of drug delivery[68].

**Nanoparticles**: Nanoparticles are engineered to cross the BBB and deliver drugs directly to affected brain regions. These particles can be designed to release drugs in a controlled manner, reducing side effects and improving therapeutic outcomes[44,9]. For example, lipid-based nanoparticles are being investigated for the delivery of siRNA to silence disease-related genes in Huntington's disease. Polymer-based nanoparticles are also being explored for their ability to carry neuroprotective agents to targeted brain areas in Alzheimer's disease[69].

**Biodegradable Implants**: Biodegradable implants offer another promising approach for localized drug delivery. These implants can be surgically placed in the brain or spinal cord, releasing drugs over an extended period. For instance, Gliadel wafers, used in the treatment of glioblastoma, are implanted at the tumor site to deliver chemotherapy directly to the tumor, minimizing systemic toxicity[70].

**Targeted Delivery Systems**: Advances in molecular biology have led to the development of targeted delivery systems that can recognize and bind to specific cell types. Antibody-drug conjugates (ADCs) are designed to deliver cytotoxic drugs to cells expressing particular surface proteins. In neurological disorders, ADCs targeting amyloid-beta plaques or tau tangles in Alzheimer's disease are being explored. Another approach involves using exosomes, which are naturally occurring vesicles that can cross the BBB, to deliver therapeutic agents to specific brain cells[72].

**Personalized Medicine**

**Tailoring Treatments Based on Genetic and Biomarker Information**: Personalized medicine aims to customize treatments based on individual genetic profiles, biomarker data, and other personal health information, offering a more precise and effective approach to managing neurological disorders[73].

**Genomic Sequencing**: Advances in genomic sequencing have made it possible to identify genetic mutations associated with various neurological disorders[7]. This information can guide the selection of targeted therapies. For example, patients with certain mutations in the LRRK2 gene in Parkinson's disease may benefit from LRRK2 inhibitors currently in

development[55]. Similarly, genetic testing for mutations in genes like APP, PSEN1, and PSEN2 can identify individuals at risk for familial Alzheimer's disease, allowing for early intervention and monitoring[74].

**Biomarkers**: Biomarkers play a crucial role in personalized medicine by providing measurable indicators of disease presence, progression, and response to treatment. In Alzheimer's disease, biomarkers such as amyloid-beta and tau levels in cerebrospinal fluid (CSF) and blood can aid in early diagnosis and monitor the effectiveness of therapeutic interventions[20]. In MS, neurofilament light chain (NfL) levels in blood and CSF reflect neuronal damage and can guide treatment decisions[75].

**Pharmacogenomics**: Pharmacogenomics examines how genetic variations influence an individual's response to drugs. This field is particularly relevant in epilepsy, where genetic differences can affect drug metabolism and efficacy[33]. For instance, patients with specific variants in the SCN1A gene may respond better to certain antiepileptic drugs, allowing for more tailored and effective treatment plans[44,9,10].

**AI and Machine Learning**: Artificial intelligence (AI) and machine learning algorithms are being used to analyze vast amounts of genetic, biomarker, and clinical data to identify patterns and predict treatment responses[20,5]. These technologies can help develop personalized treatment plans and optimize therapeutic strategies. For example, AI algorithms can predict which Parkinson's disease patients are most likely to benefit from deep brain stimulation based on their clinical and genetic profiles[76].

## 2. CONCLUSION

Over the past few decades, significant strides have been made in understanding and treating neurological disorders. Advances in pharmacological, non-pharmacological, and surgical interventions have markedly improved patient outcomes. For instance, disease-modifying therapies for multiple sclerosis (MS) and deep brain stimulation (DBS) for Parkinson's disease have been revolutionary. Breakthroughs in neuroimaging and molecular biology have further deepened our understanding of these diseases, enabling more targeted treatments. Despite these advancements, several challenges persist. Neurological disorders are inherently complex, involving multifaceted biological processes and diverse clinical presentations. This complexity hampers the development of universally effective therapies. Traditional research methods often fail to capture this complexity, leading to high failure rates in drug development. Additionally, the blood-brain barrier (BBB) restricts the delivery of therapeutic agents to the central nervous system, posing a significant obstacle. Clinical and regulatory hurdles also impede progress. Designing and executing clinical trials for neurological disorders is challenging due to the need for long-term studies to observe meaningful outcomes, the subjective nature of many symptoms, and difficulties in recruiting and retaining participants. The rigorous regulatory approval process, while essential for ensuring safety and efficacy, can delay the availability of new therapies. The review article on microneedle therapy for neurological disorders concludes that microneedle technology represents a transformative advancement in the delivery of therapeutics for neurological conditions. The unique advantages of microneedles, such as their minimally invasive nature and ability to bypass the blood-brain barrier, enhance drug delivery efficacy while minimizing patient discomfort. Overall, while microneedle therapy is still in its developmental stages, its potential to revolutionize the management of neurological disorders warrants continued exploration and investment.

## 3. REFERENCES


1. J.H. Park, Y.K. Yoon, S.O. Choi, M.R. Prausnitz, and M.G. Allen, "Tapered conical polymer microneedles fabricated using an integrated lens technique for transdermal drug delivery," *IEEE Trans. Bio-Med. Eng.*, vol. 54, no. 5, pp. 903–913, May 2007. doi: 10.1109/TBME.2006.889173.
2. S.P. Sullivan, N. Murthy, and M.R. Prausnitz, "Minimally invasive protein delivery with rapidly dissolving polymer microneedles," *Adv. Mater.*, vol. 20, no. 7, pp. 933–938, Feb. 2008. doi: 10.1002/adma.200701205.
3. K. Lee and H. Jung, "Drawing lithography for microneedles: A review of fundamentals and biomedical applications," *Biomaterials*, vol. 33, no. 27, pp. 7309–7326, Sep. 2012. doi: 10.1016/j.biomaterials.2012.06.065.
4. C.J. Martin, C.J. Allender, K.R. Brain, A. Morrissey, and J.C. Birchall, "Low temperature fabrication of biodegradable sugar glass microneedles for transdermal drug delivery applications," *J. Control. Release*, vol. 158, no. 1, pp. 93–101, Jan. 2012. doi: 10.1016/j.jconrel.2011.10.024.
5. J.D. Kim, M. Kim, H. Yang, K. Lee, and H. Jung, "Droplet-born air blowing: Novel dissolving microneedle fabrication," *J. Control. Release*, vol. 170, no. 3, pp. 430–436, Jun. 2013. doi: 10.1016/j.jconrel.2013.05.026.
6. R. Vecchione, S. Coppola, E. Esposito, C. Casale, V. Vespini, S. Grilli, P. Ferraro, and P.A. Netti, "Electro-drawn drug-loaded biodegradable polymer microneedles as a viable route to hypodermic injection," *Adv. Funct. Mater.*, vol. 24, no. 22, pp. 3515–3523, Nov. 2014. doi: 10.1002/adfm.201303679.
7. Bonificio, E. Ghartey-Tagoe, S. Gallorini, B. Baudner, G. Chen, P. Singh, D.T. O'Hagan, and S. Kommareddy, "Fabrication of cell culture-derived influenza vaccine dissolvable microstructures and evaluation of immunogenicity in guinea pigs," *Vaccine*, vol. 33, no. 25, pp. 2930–2938, Jun. 2015. doi: 10.1016/j.vaccine.2015.04.059.
8. M.C. Chen, M.H. Ling, and S.J. Kusuma, "Poly-γ-glutamic acid microneedles with a supporting structure design as a potential tool for transdermal delivery of insulin," *Acta Biomater.*, vol. 24, pp. 106–116, Jul. 2015. doi: 10.1016/j.actbio.2015.06.021.
9. J. Yu, Y. Zhang, Y. Ye, R. DiSanto, W. Sun, D. Ranson, F.S. Ligler, J.B. Buse, and Z. Gu, "Microneedle-array patches loaded with hypoxia-sensitive vesicles provide fast glucose-responsive insulin delivery," *Proc. Natl. Acad. Sci. USA*, vol. 112, no. 26, pp. 8260–8265, Jun. 2015. doi: 10.1073/pnas.1505405112.
10. Vrdoljak, E.A. Allen, F. Ferrara, N.J. Temperton, A.M. Crean, and A.C. Moore, "Induction of broad immunity by thermostabilised vaccines incorporated in dissolvable microneedles using novel fabrication methods," *J. Control. Release*, vol. 225, pp. 192–204, Mar. 2016. doi: 10.1016/j.jconrel.2016.01.019.
11. S. Bhatnagar, K. Dave, and V.V.K. Venuganti, "Microneedles in the clinic," *J. Control. Release*, vol. 260, pp. 164–182, Jun. 2017. doi: 10.1016/j.jconrel.2017.05.029.
12. X. Xie, C. Pascual, C. Lieu, S. Oh, J. Wang, B. Zou, J. Xie, Z. Li, J. Xie, D.C. Yeomans, et al., "Analgesic Microneedle Patch for Neuropathic Pain Therapy," *ACS Nano*, vol. 11, no. 1, pp. 395–406, Jan. 2017. doi: 10.1021/acsnano.6b06104.
13. I.C. Lee, W.M. Lin, J.C. Shu, S.W. Tsai, C.H. Chen, and M.T. Tsai, "Formulation of two-layer dissolving polymeric microneedle patches for insulin transdermal delivery in diabetic mice," *J. Biomed. Mater. Res. Part A*, vol. 105, no. 1, pp. 84–93, Jan. 2017. doi: 10.1002/jbm.a.35869.
14. D. Poirier, F. Renaud, V. Dewar, L. Strodiot, F. Wauters, J. Janimak, T. Shimada, T. Nomura, K. Kabata, K. Kuruma, et al., "Hepatitis B surface antigen incorporated in

dissolvable microneedle array patch is antigenic and thermostable," *Biomaterials*, vol. 145, pp. 256–265, Oct. 2017. doi: 10.1016/j.biomaterials.2017.08.038.

15. Y. Zhang, P. Feng, J. Yu, J. Yang, J. Zhao, J. Wang, Q. Shen, and Z. Gu, "Thrombin-Responsive Transcutaneous Patch for Auto-Anticoagulant Regulation," *Adv. Mater.*, vol. 29, no. 32, pp. 1604043, Jul. 2017. doi: 10.1002/adma.201604043.
16. Mandal, A.V. Boopathy, L.K.W. Lam, K.D. Moynihan, M.E. Welch, N.R. Bennett, M.E. Turvey, N. Thai, J.H. Van, and J.C. Love, "Cell and fluid sampling microneedle patches for monitoring skin-resident immunity," *Sci. Transl. Med.*, vol. 10, no. 429, eaar2227, Mar. 2018. doi: 10.1126/scitranslmed.aar2227.
17. N.W. Kim, S.Y. Kim, J.E. Lee, Y. Yin, J.H. Lee, S.Y. Lim, E.S. Kim, H.T.T. Duong, H.K. Kim, S. Kim, et al., "Enhanced Cancer Vaccination by In Situ Nanomicelle-Generating Dissolving Microneedles," *ACS Nano*, vol. 12, no. 9, pp. 9702–9713, Sep. 2018. doi: 10.1021/acsnano.8b04146.
18. Y. Zhang, P. Feng, J. Yu, J. Yang, J. Zhao, J. Wang, Q. Shen, and Z. Gu, "Ros-responsive microneedle patch for acne vulgaris treatment," *Adv. Ther.*, vol. 1, no. 3, 1800035, Nov. 2018. doi: 10.1002/adtp.201800035.
19. D. Al Sulaiman, J.Y.H. Chang, N.R. Bennett, H. Topouzi, C.A. Higgins, D.J. Irvine, and S. Ladame, "Hydrogel-Coated Microneedle Arrays for Minimally Invasive Sampling and Sensing of Specific Circulating Nucleic Acids from Skin Interstitial Fluid," *ACS Nano*, vol. 13, no. 8, pp. 9620–9628, Aug. 2019. doi: 10.1021/acsnano.9b04783.
20. M.A. Lopez-Ramirez, F. Soto, C. Wang, R. Rueda, S. Shukla, C. Silva-Lopez, D. Kupor, D.A. McBride, J.K. Pokorski, A. Nourhani, et al., "Built-In Active Microneedle Patch with Enhanced Autonomous Drug Delivery," *Adv. Mater.*, vol. 32, no. 13, p. e1905740, Apr. 2020. doi: 10.1002/adma.201905740.
21. T. Wan, Q. Pan, and Y. Ping, "Microneedle-assisted genome editing: A transdermal strategy of targeting NLRP3 by CRISPR-Cas9 for synergistic therapy of inflammatory skin disorders," *Sci. Adv.*, vol. 7, no. 14, p. eabe2888, Apr. 2021. doi: 10.1126/sciadv.abe2888.
22. S. Kusama, K. Sato, Y. Matsui, N. Kimura, H. Abe, S. Yoshida, and M. Nishizawa, "Transdermal electroosmotic flow generated by a porous microneedle array patch," *Nat. Commun.*, vol. 12, no. 1, p. 658, Jan. 2021. doi: 10.1038/s41467-021-20948-4.
23. H. Chang, S.W.T. Chew, M. Zheng, D.C.S. Lio, C. Wiraja, Y. Mei, X. Ning, M. Cui, A. Than, P. Shi, et al., "Cryomicroneedles for transdermal cell delivery," *Nat. Biomed. Eng.*, vol. 5, no. 9, pp. 1008–1018, Sep. 2021. doi: 10.1038/s41551-021-00720-1.
24. M.R. Prausnitz, "Microneedles for transdermal drug delivery," *Adv. Drug Deliv. Rev.*, vol. 56, no. 5, pp. 581–587, Mar. 2004. doi: 10.1016/j.addr.2003.10.023.
25. R.F. Donnelly, T.R. Singh, M.J. Garland, K. Migalska, R. Majithiya, C.M. McCrudden, P.L. Kole, T.M. Mahmood, H.O. McCarthy, and A.D. Woolfson, "Hydrogel-Forming Microneedle Arrays for Enhanced Transdermal Drug Delivery," *Adv. Funct. Mater.*, vol. 22, no. 22, pp. 4879–4890, Nov. 2012. doi: 10.1002/adfm.201200864.
26. V. Kumar *et al.*, "Neuroprotective Effect of Boswellia serrata against 3-NP Induced Experimental Huntington's Disease," *Current bioactive compounds*, vol. 20, Jan. 2024, doi: https://doi.org/10.2174/0115734072272233231119161319.
27. P. Bhatt, V. Kumar, S. Singh, and Kunal Kanojia, "Climatic/Meteorological Conditions and Their Role in Biological Contamination," pp. 56–88, Jun. 2024, doi: https://doi.org/10.1002/9781394178964.ch4.
28. Dharmendra Bhati *et al.*, "FUSED AND SUBSTITUTED PYRIMIDINE DERIVATIVES AS POTENT ANTICANCER AGENTS," *Biochemical and Cellular Archives/Biochemical and cellular archives*, vol. 24, no. 1, Jan. 2024, doi: https://doi.org/10.51470/bca.2024.24.1.749.

29. K. J. Mangala *et al.*, "NANOCELLULOSE: A VERSATILE AND SUSTAINABLE CARRIER FOR DRUG AND BIOACTIVE COMPOUNDS," *Biochemical and Cellular Archives/Biochemical and cellular archives*, vol. 24, no. 1, Jan. 2024, doi: https://doi.org/10.51470/bca.2024.24.1.553.
30. Rohit Kumar Trivedi *et al.*, "REVOLUTIONIZING DRUG DELIVERY THROUGH 3D PRINTING TECHNOLOGY: CURRENT ADVANCES AND FUTURE DIRECTIONS," *Biochemical and Cellular Archives/Biochemical and cellular archives*, vol. 24, no. 1, Jan. 2024, doi: https://doi.org/10.51470/bca.2024.24.1.521.
31. H. Rastogi, P. Bhatt, S. Garg, S. Kamboj, V. Deva, and R. Goel, "EXPLORING THE POTENTIAL OF QUANTUM DOTS AS LUMINOUS PROBES FOR TARGETED DRUG DELIVERY AND BIOIMAGING IN CLINICAL DIAGNOSTICS," *Biochemical and Cellular Archives/Biochemical and cellular archives*, vol. 24, no. 1, Jan. 2024, doi: https://doi.org/10.51470/bca.2024.24.1.457.
32. M. shama, "CRISPR-Cas9 gene editing in pharmaceuticals : Current applications and future prospects," *Biochemical and Cellular Archives/Biochemical and cellular archives*, vol. 23, no. S1, Dec. 2023, doi: https://doi.org/10.51470/bca.2023.23.s1.1655.
33. S. Arora, Saiphali, G. Dharmamoorthy Dharmendra Bhati, T. Gupta, and P. Bhatt, "Advancements in peptide-based therapeutics: Design, synthesis and clinical applications," *Biochemical and Cellular Archives/Biochemical and cellular archives*, vol. 23, no. S1, Dec. 2023, doi: https://doi.org/10.51470/bca.2023.23.s1.1415.
34. M. Singhal et al., "Formulation development and characterization of powder for oral suspension containing H2 blocker drug to combat GERD and peptic ulcer," NeuroQuantology, vol. 20, no. 11, pp. 1258, 2022.
35. S. Ahamed, P. Bhatt, S. J. Sultanuddin, R. Walia, M. A. Haque, and S. B. InayathAhamed, "An Intelligent IoT enabled Health Care Surveillance using Machine Learning," in 2022 International Conference on Advances in Computing, Communication and Applied Informatics (ACCAI). IEEE, 2022.
36. V. Ahmed, S. Sharma, and P. Bhatt, "Formulation and evaluation of sustained release tablet of diltiazem hydrochloride," International Journal of Pharmaceutical Sciences and Research, vol. 11, no. 5, pp. 2193–2198, 2020.
37. A. E. Al-Snafi, S. Singh, P. Bhatt, and V. Kumar, "A review on prescription and non-prescription appetite suppressants and evidence-based method to treat overweight and obesity," GSC biol pharm sci, vol. 19, no. 3, pp. 148–155, 2022.
38. B. Baskar, S. Ramakrishna, and A. Daniela La Rosa, Eds., Encyclopedia of green materials. Singapore: Springer Nature Singapore, 2022.
39. P. Bhatt et al., "Nanorobots recent and future advances in cancer or dentistry therapy- A review," Am J PharmTech Res, vol. 9, no. 3, pp. 321–331, 2019.
40. P. Bhatt et al., "Citrus Flavonoids: Recent Advances and Future Perspectives On Preventing Cardiovascular Diseases," in The Flavonoids, 2024, pp. 131-152.
41. P. Bhatt et al., "Functional and tableting properties of alkali-isolated and phosphorylated barnyard millet (Echinochloa esculenta) starch," ACS Omega, vol. 8, no. 33, pp. 30294–305, 2023.
42. P. Bhatt et al., "Plasma modification techniques for natural polymer-based drug delivery systems," Pharmaceutics, vol. 15, no. 8, p. 2066, 2023.
43. P. Bhatt et al., "Comparative study and in vitro evaluation of sustained release marketed formulation of aceclofenac sustained release tablets," Pharma Science Monitor, vol. 9, no. 2, 2018.

44. P. Bhatt et al., "Development and characterization of fast dissolving buccal strip of frovatriptan succinate monohydrate for buccal delivery," Int J Pharm Investig, vol. 11, no. 1, pp. 69–75, 2021.
45. P. Bhatt et al., "Artificial intelligence in pharmaceutical industry: Revolutionizing drug development and delivery," The Chinese Journal of Artificial Intelligence, 2023.
46. P. Bhatt et al., "Blockchain technology applications for improving quality of electronic healthcare system," in Blockchain for Healthcare Systems, 2021, pp. 97–113.
47. P. Bhatt, "Mouth Dissolving Tablets Challenges, Preparation Strategies with a Special Emphasis on Losartan Potassium–A Review," World J. Pharm. Pharm. Sci, vol. 7, no. 9, pp. 271-287, 2018.
48. C. Goyal et al., "Estimation of shelf-life of Balachaturbhadrika syrup containing different sweetening agents," Res J Pharm Technol, pp. 5078–5083, 2022.
49. T. Kaur and S. Singh, "Controlled release of bi-layered malvidin tablets using 3D printing techniques," J Pharm Res Int, pp. 70–78, 2021.
50. M. Kaurav et al., "In-depth analysis of the chemical composition, pharmacological effects, pharmacokinetics, and patent history of mangiferin," Phytomed Plus, vol. 3, no. 2, p. 100445, 2023.
51. A. Kumar, P. Bhatt, and N. Mishra, "Irritable bowel Syndrome with reference of Alosetron Hydrochloride and Excipient profile used in the manufacturing of Alosetron tablet-A review," J Chem Pharm Sci, vol. 12, no. 03, pp. 71–78, 2019.
52. M. K. Malik et al., "Significance of chemically derivatized starch as drug carrier in developing novel drug delivery devices," Nat Prod J, 2022.
53. M. K. Malik et al., "Preclinical safety assessment of chemically cross-linked modified mandua starch: Acute and sub-acute oral toxicity studies in Swiss albino mice," ACS Omega, vol. 7, no. 40, pp. 35506–35514, 2022.
54. M. K. Malik et al., "Phosphorylation of alkali extracted mandua starch by STPP/STMP for improving digestion resistibility," ACS Omega, vol. 8, no. 13, pp. 11750–11767, 2023.
55. Pankaj, "Anti-cancer cyclodextrin nanocapsules based formulation development for lung chemotherapy," J Pharm Res Int, pp. 54–63, 2021.
56. Pankaj, "Cyclodextrin modified block polymer for oral chemotherapy," J Pharm Res Int, pp. 21–29, 2021.
57. V. Raghuwanshi et al., "Recent Advances In Nanotechnology For Combating Against Corona Virus Infection," Journal of Pharmaceutical Negative Results, pp. 1811-1820, 2022.
58. K. K. Sahu et al., "Utility of nanomaterials in wound management," in Nanotechnological Aspects for Next-Generation Wound Management, 2024, pp. 101–130.
59. S. K. Sharma et al., "Combined therapy with ivermectin and doxycycline can effectively alleviate the cytokine storm of COVID-19 infection amid vaccination drive: A narrative review," J Infect Public Health, vol. 15, no. 5, pp. 566–572, 2022.
60. S. K. Sharma and P. Bhatt, "Controlled release of bi-layered EGCG tablets using 3D printing techniques," J Pharm Res Int, pp. 5–13, 2021.
61. S. K. Sharma and S. Singh, "Antimicrobial Herbal Soap Formulation," Journal of Pharmaceutical Research International, vol. 32, no. 36, pp. 82-88, 2022.
62. S. Singh et al., "Cardiovascular comorbidity of COVID-19 disease: A review," WJPMR, vol. 8, no. 4, pp. 216–225, 2022.
63. S. Singh et al., "Phytonutrients, Anthocyanidins, and Anthocyanins: Dietary and Medicinal Pigments with Possible Health Benefits," in Advances in Flavonoids for Human Health and Prevention of Diseases, 2024, pp. 23-46.
64. S. Singh et al., "Digital Transformation in Healthcare: Innovation and Technologies," in Blockchain for Healthcare Systems, 2021, pp. 61–79.

65. S. Singh et al., "Alginate based Nanoparticles and Its Application in Drug Delivery Systems," Journal of Pharmaceutical Negative Results, pp. 1463-1469, 2022.
66. R. Johari et al., "Artificial Intelligence and Machine Learning in Drug Discovery and Development," in 2023 12th International Conference on System Modeling & Advancement in Research Trends (SMART), 2023, pp. 556-561.
67. P. Bhatt et al., "Impact of Cross-Linking on the Physicochemical and Physiological Characteristics of Barnyard Millet (Echinochloa frumentacea) Grains Starch," Stärke/Starch, May 2024, doi: https://doi.org/10.1002/star.202300285.
68. V. Kumar et al., "Ultrasound assisted techniques for starch modification to develop novel drug delivery systems: A comprehensive study," Journal of bioactive and compatible polymers, May 2024, doi: https://doi.org/10.1177/08839115241249143.
69. Y.C. Kim, J.H. Park, and M.R. Prausnitz, "Microneedles for drug and vaccine delivery," *Adv. Drug Deliv. Rev.*, vol. 64, no. 14, pp. 1547–1568, Oct. 2012. doi: 10.1016/j.addr.2012.04.005.
70. R.F. Donnelly, M.T. McCrudden, A. Zaid Alkilani, E. Larrañeta, E. McAlister, A.J. Courtenay, M.C. Kearney, T.R. Singh, H.O. McCarthy, V.L. Kett, et al., "Hydrogel-forming microneedles prepared from 'super swelling' polymers combined with lyophilised wafers for transdermal drug delivery," *PLoS ONE*, vol. 9, no. 1, p. e111547, Jan. 2014. doi: 10.1371/journal.pone.0111547.
71. J. Li, M. Zeng, H. Shan, and C. Tong, "Microneedle Patches as Drug and Vaccine Delivery Platform," *Curr. Med. Chem.*, vol. 24, no. 22, pp. 2413–2422, Jun. 2017. doi: 10.2174/0929867324666170526124053.
72. B.K. Meyer, M.A.F. Kendall, D.M. Williams, A.J. Bett, S. Dubey, R.C. Gentzel, D. Casimiro, A. Forster, H. Corbett, M. Crichton, et al., "Immune response and reactogenicity of an unadjuvanted intradermally delivered human papillomavirus vaccine using a first generation Nanopatch™ in rhesus macaques: An exploratory, pre-clinical feasibility assessment," *Vaccine: X*, vol. 2, p. 100030, Dec. 2019. doi: 10.1016/j.jvacx.2019.100030.
73. S. Ross, N. Scoutaris, D. Lamprou, D. Mallinson, and D. Douroumis, "Inkjet printing of insulin microneedles for transdermal delivery," *Drug Deliv. Transl. Res.*, vol. 5, no. 5, pp. 451–461, Oct. 2015. doi: 10.1007/s13346-015-0251-1.
74. P.E. Daddona, J.A. Matriano, J. Mandema, and Y.F. Maa, "Parathyroid hormone (1-34)-coated microneedle patch system: Clinical pharmacokinetics and pharmacodynamics for treatment of osteoporosis," *Pharm. Res.*, vol. 28, no. 1, pp. 159–165, Jan. 2011. doi: 10.1007/s11095-010-0192-9.
75. Z. Wang, J. Luan, A. Seth, L. Liu, M. You, P. Gupta, R. Rathi, Y. Wang, S. Cao, Q. Jiang, et al., "Microneedle patch for the ultrasensitive quantification of protein biomarkers in interstitial fluid," *Nat. Biomed. Eng.*, vol. 5, no. 1, pp. 64–76, Jan. 2021. doi: 10.1038/s41551-020-00672-y.
76. D.V. McAllister, P.M. Wang, S.P. Davis, J.H. Park, P.J. Canatella, M.G. Allen, and M.R. Prausnitz, "Microfabricated needles for transdermal delivery of macromolecules and nanoparticles: Fabrication methods and transport studies," *Proc. Natl. Acad. Sci. USA*, vol. 100, no. 24, pp. 13755–13760, Nov. 2003. doi: 10.1073/pnas.2331316100.